Section Arrow
Quote
HRMY.NASDAQ
- Harmony Biosciences Holdings
Quotes are at least 15-min delayed:2025/07/20 16:53 EDT
Regular Hours
Last
 35.2
-1.23 (-3.38%)
Day High 
37.21 
Prev. Close
36.43 
1-M High
36.71 
Volume 
701.76K 
Bid
34.75
Ask
36.5
Day Low
35.09 
Open
36.45 
1-M Low
31.25 
Market Cap 
2.09B 
Currency USD 
P/E 13.9 
%Yield -- 
10-SMA 34.1 
20-SMA 33.02 
50-SMA 33.84 
52-W High 41.61 
52-W Low 26.47 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
2.62/4.40
Enterprise Value
2.25B
Balance Sheet
Book Value Per Share
12.55
Cash Flow
Cash Flow Yield
0.11
Income Statement
Total Revenue
714.73M
Operating Revenue Per Share
9.44
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed：2025/07/20 16:53 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX(pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.